Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Different CagriSema Presentations in Adults With Overweight or Obesity
NCT06716307Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2024
- Primary completion
- Mar 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of cagrilintide and semaglutide in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the cagrilintide concentration-time curve, Maximum concentration of cagrilintide and 2 more. Started Dec 2024; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06716307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716307.